01985nas a2200253   4500000000100000008004100001653001500042653001800057653001200075653002300087653001200110653001000122100001400132700001200146700001300158700001300171700001200184700001100196700001200207245007500219300001200294490000700306520141800313       2015                            d10aSkin smear10aSkin biopsies10aRelapse10aMulti drug therapy10aleprosy10aIndia1 aKuldeep C1 aKhare A1 aTantia J1 aMittal A1 aGupta L1 aGarg A1 aMehta S00aA retrospective study about relapse among MDT treated leprosy patient.  a24–280 v683 a<div>
<p>Background: New skin or nerve lesions may develop despite the fixed duration of multi drug therapy (MDT), in multibacillary (MB) and paucibacillary (PB) leprosy. The lesions could be due to reaction, relapse or reinfection. The index study was conducted to know the percentage of relapse in leprosy at a tertiary care hospital in Southern Rajasthan, India.<br />
Material and Methods: The study was conducted on 29 (4 PB and 25 MB) cases, who had completed WHO guided fixed duration MDT regimens and were under regular surveillance for more than one year. Besides the relapse criteria laid by Beck-Bleumink, we performed slit skin smear (BI) and skin biopsy. Study spanned from January 2005 to December 2006.<br />
Observations: Two MB cases (8%) evidenced features of clinical as well as bacteriological relapse, but none of the PB cases relapsed. The overall relapse rate was 6.9%. Relapsed patients reported after 1 and 5 years of release from treatment (RFT) and their newer clinical and bacteriological status was also lepromatous leprosy (LL) with BI 4+.<br />
Conclusions: MDT is quite effective for treatment of leprosy, however, possibility of relapse is still there. Relapse rate showed wide variation in different studies.<br />
<a href="http://theindianpractitioner.com/index.php/tip/article/view/62945">http://theindianpractitioner.com/index.php/tip/article/view/62945</a></p>
</div>